Medicare just proved it can force Big Pharma to slash prices by as much as 71%, fundamentally reshaping how America pays for prescription drugs.
Story Overview
- Medicare successfully negotiated prices for 15 drugs in its second cycle, with all manufacturers agreeing to participate
- Ozempic and Wegovy received a massive 71% price reduction, representing one of the largest negotiated cuts to date
- The negotiated prices take effect in 2027 and will save Medicare billions while reducing out-of-pocket costs for 49 million beneficiaries
- This expansion follows a successful first cycle that achieved minimum 38% reductions on 10 drugs, proving the program’s sustainability
A Historic Shift in Pharmaceutical Power
The Centers for Medicare and Medicaid Services announced in March 2025 that agreements were signed with all 15 drug manufacturers selected under the second cycle of the Medicare Drug Price Negotiation Program. This achievement represents a fundamental power shift in pharmaceutical pricing, where Medicare now wields collective bargaining strength representing 49 million beneficiaries against an industry that previously held near-absolute pricing control.
The program stems from the Inflation Reduction Act of 2022, which overturned nearly two decades of restrictions that prohibited Medicare from negotiating drug prices. Prior to this legislation, the “noninterference clause” from 2003 locked Medicare into paying whatever prices pharmaceutical companies demanded, creating a system where the largest government healthcare purchaser had no bargaining power.
Watch:
Blockbuster Drugs Face Steep Price Cuts
The second negotiation cycle targeted high-cost medications without generic competition, focusing on drugs that drain the largest portions of Medicare spending. The inclusion of Ozempic and Wegovy, blockbuster diabetes and weight management drugs, demonstrates the program’s reach into the most expensive medication categories. The reported 71% price reduction for these semaglutide products far exceeds the minimum 38% reductions achieved in the first cycle.
This dramatic price cut signals that Medicare negotiators are becoming more aggressive and effective at extracting substantial savings from manufacturers. The universal participation of all 15 selected companies indicates that pharmaceutical companies view continued access to Medicare’s massive patient base as more valuable than refusing to negotiate, despite the revenue impact.
Medicare negotiated lower prices for 15 drugs, including 71% off Ozempic and Wegovy – Medicare announced 15 lower drugs after a second round of negotiations with pharmaceutical companies. The drugs include Ozempic and also drugs to treat asthma, breast c… https://t.co/Q6nxG72vyX
— 🌊💙 Viking Resistance 💙🌊 (@BlueCrewViking) November 26, 2025
Proven Track Record Builds Momentum
The first negotiation cycle, completed in 2024, established crucial precedents that enabled this second cycle’s success. All 10 manufacturers in the initial round participated and agreed to price reductions, saving Medicare beneficiaries $1.5 billion annually in out-of-pocket costs while saving the Medicare program $6 billion per year. These results validated the program’s effectiveness and demonstrated that manufacturers would comply rather than forfeit market access.
The negotiation process follows a structured timeline where drug companies submit information by February, CMS issues initial price offers by June, and negotiations conclude by November.
Expanding Impact and Political Resistance
The program continues expanding with up to 15 additional drugs selected for 2028 negotiations, followed by up to 20 drugs annually beginning in 2029. This escalating schedule creates cumulative savings that will grow substantially as more medications face price negotiations. However, political resistance remains significant, with the 2025 budget reconciliation bill reducing the program’s effectiveness by limiting which drugs can be negotiated.
Sources:
Centers for Medicare and Medicaid Services – Selected Drugs Negotiated Prices
Commonwealth Fund – Medicare Drug Price Negotiations Explainer
Medicare Rights Center – Negotiated Prices Take Effect
Journal of Managed Care & Specialty Pharmacy
Kaiser Family Foundation – Medicare Drug Price Negotiation FAQs
CMS Infographic – Negotiated Prices 2027
